Kornimate/medical-research-clean huggingface dataset:
emergency pancreaticoduodenectomy: a non-trauma center case series

Conditions: Emergencies; Pancreas Disease

Summary: pancreaticoduodenectomy is a challenging procedure itself, being even more complex and demanding in emergency settings. only a few cases of emergency pancreaticoduodenectomy (epd) are reported in medical literature, usually performed for complex pancreaticoduodenal lesions. epd has first been mentioned in trauma settings, even fewer cases being reported for non-traumatic indications. the investigators intend to present our experience with this intervention, in a non-trauma surgical centre. our study is a prospective consecutive case series, that included patients that underwent emergency pancreaticoduodenectomy from january 2014 to may 2021. data was collected from the electronic system database. the investigators collected data regarding the demographic characteristics of the patients, their medical history, preoperative and postoperative investigations (including blood work and imagistic investigations), surgery related information and postoperative evolution.


Eligibility criteria:
inclusion criteria: * emergency pancreaticoduodenectomy performed exclusion criteria: * elective surgery * insufficient data
a phase i study of mgcd0103 given twice weekly in patients with leukemia or myelodysplastic syndromes

Conditions: Leukemia; Myelodysplastic Syndromes

Summary: in this study, mgcd0103, a new anticancer drug under investigation, is given twice weekly to patients with leukemia or myelodysplastic syndromes.


Eligibility criteria:
inclusion criteria: * patients must have a diagnosis of one of the following: * relapsed or refractory aml or all that has failed to respond to standard therapy, has progressed despite standard therapy. * relapsed or refractory myelodysplastic syndromes including cmml (chronic myelomonocytic leukemia) or other myeloproliferative disorders provided there is an mds component. * previously untreated aml or myelodysplastic syndromes in patients \>60 years of age who refused or are not candidates for induction chemotherapy * patients with relapsed or refractory cml that has failed to respond to imatinib therapy or standard therapy, has progressed despite standard therapy, or for which no standard therapy exists. * ecog performance status of 0, 1, or 2. * age ≥18 years. * laboratory requirements. * patients or their legal representative must be able to read, understand, and sign a written informed consent (approved by the irb/ec) prior to study entry. exclusion criteria: * patients with other active malignancy except basal cell carcinoma or cervical intraepithelial neoplasia (cin / cervical in situ). * patients with suspicion of cns involvement (tests are not required to rule out cns involvement in the absence of signs or symptoms). * pregnant or lactating women. women of child-bearing potential must have a negative serum pregnancy test documented within 7 days prior to registration on study. * patients and their partners, if either are of childbearing potential, not using adequate birth control measures throughout the course of the study. both men and women enrolled on study must agree to use a medically acceptable effective form of contraception during the study and for 90 days following the last dose of study medication. an effective form of contraception is an oral contraceptive or a double barrier method, such as condom with diaphragm. * patients with serious illnesses, medical conditions, or other medical history, including laboratory results, which, in the investigator's opinion, would be likely to interfere with a patient's participation in the study, or with the interpretation of the results. * patients who have been treated with any investigational drug within 30 days prior to study initiation (an investigational drug is one for which there is no approved indication), or who are receiving concurrent treatment with other experimental drugs or anti-cancer therapy. * known hypersensitivity to any of the components of mgcd0103. * known hiv or hepatitis b or c (tests do not need to be performed to rule out any of these infections). * any psychiatric illness/social situations that would, in the judgment of the investigator, limit compliance with study requirements.

Keywords: leukemia myelodysplastic syndromes phase i
anticoagulation in emergency general surgery

Conditions: Emergency General Surgery

Summary: while doacs are increasing in use in the egs patient population, the risk of bleeding and the reversal of these agents to reduce hemorrhage is still evolving. given the paucity of data regarding the impact of doacs in this patient population, it becomes empiric to identify bleeding patterns and outcomes in the egs population taking doacs. we hypothesize that patients taking a doac will have a higher bleeding incidence and need for an unplanned intervention secondary to hemorrhage in egs patients undergoing an urgent or emergent operation when compared to patients taking warfarin and antiplatelets.

emergency general surgery (egs) represents illnesses of diverse pathology with urgent/emergent treatment needs being the common denominator.a characteristic feature of egs is its limitation in patient preparation. it is difficult and often impossible to eliminate certain patient dependent factors to reduce the operative risk. it has been reported that the annual case rate in the egs population is (1,290 per 100,000) higher than the sum of all cancer diagnoses. the egs burden is substantial and continues to increase. the elderly patient population represents 48% of the overall egs population. with the increase in the prevalence of atherosclerotic disease in the elderly there has been an increase in the use of antiplatelets and anticoagulants.

Eligibility criteria:
inclusion criteria: * all patients who are confirmed to be taking dabigatran, rivaroxaban, apixaban, warfarin and antiplatelet therapy (aspirin, clopidogril, ticagrelor) undergoing an urgent or emergent surgical intervention by the emergency general surgery service within 24 hours of arrival to the hospital * 18 years of age or over exclusion criteria: * prisoners * pregnant patients * those who received an index operation at an outside facility and were transferred * under 18 years of age
analysis of the potentially parasitocidal effect of a long term chemotherapy with benzimidazoles

Conditions: Alveolar Echinococcosis

Summary: the aim of this study is to evaluate pet-ct and emii/3-10 serology as potential markers to assess the parasitocidal effect of benzimidazoles * trial with medicinal product


Eligibility criteria:
inclusion criteria: * patients with inoperable alveolar echinococcosis * with negative pet-ct * emii/3-10 serology under long-term chemotherapy with benzimidazoles exclusion criteria: * positive pet-ct * positive emii-3-10 serology * no compliance * reduced life expectancy * pregnancy
the prognostic value of cpcs quantified by flow cytometry in patients with multiple myeloma: a prospective, multicenter clinical trial

Conditions: Multiple Myeloma

Summary: this study aims to investigate the prognostic value of circulating plasma cells (cpcs) in patients with multiple myeloma and explore whether cpcs detection might be used in place of bone marrow aspiration for disease monitoring.

circulating plasma cells (cpcs) represents a phenotypic subset of bone marrow multiple myeloma (mm) cells, which would contribute to the progression and dissemination of the tumor. high-sensitivity techniques such as multiparameter flow cytometry provide a tool for better detection of cpcs; however, a clear threshold has not been identified. the primary objective of the current study is to identify an optimal threshold for cpcs quantified by 8-color flow cytometry (with antibodies to cd38, cd138, cd45, cd56, cd19, cd27 and cytoplasmic kappa and lambda immunoglobulin light chains) and determine the specific relationship between cpcs level and the prognosis of mm. in addition, the evaluation of cpcs at multiple time points will be performed to explore whether cpcs detection might be used in place of bone marrow aspiration for disease monitoring.

Eligibility criteria:
inclusion criteria: patients must meet all of the following inclusion criteria. * newly diagnosed multiple myeloma patients. * patients without any previous anti-myeloma treatment. * age: 18-80years old (adult). * no history of cancer. * informed consent. exclusion criteria: patients meeting any of the following exclusion criteria will not be included in the study. * received therapy for multiple myeloma. * patients diagnosed with monoclonal gammopathy of undetermined significance, smoldering myeloma, nonsecretory myeloma, plasma cell leukemia, amyloidosis, waldenstrom macroglobulinemia or poems. * imminent or emerging infection. * known to be seropositive for a history of hiv. * a participant is a woman who is pregnant, breastfeeding, or planning to become pregnant while enrolled in this trial. * known or suspected of not being able to comply with the study protocol.

Keywords: multiple myeloma circulating plasma cells multiparameter flow cytometry prognosis disease monitoring
augmenting specialty eating disorder clinical treatment with a smartphone application

Conditions: Eating Disorders

Summary: cognitive behavioural therapy (cbt) is the most empirically supported and researched treatment for eating disorders. a central component of cbt for eating disorders is self-monitoring which involves patients keeping a paper food record of their meals and associated thoughts, feelings, and behaviours and receiving feedback from a clinician to help target dysfunctional cognitions and behaviours. given the issues associated with paper journals such as non-compliance, feelings of shame when used in public, and delayed feedback, researchers have developed an evidence-based smartphone application (recovery record) for eating disorder self-monitoring that links patients with their clinicians and offers additional features designed to enhance treatment. the current pilot randomised controlled trial (rct) seeks to evaluate this smartphone application in a clinical setting alongside standard eating disorder outpatient treatment. patients will be recruited from the nova scotia health authority eating disorder outpatient program and randomised to receive either standard treatment or standard treatment with the app (instead of the paper food record). the efficacy and acceptability of both treatments will be assessed and compared. coping skill use and self-efficacy among patients will also be examined given the skill building focus of treatment and in-app capabilities to deliver real-time coping skill suggestions to patients. this pilot study will be the first to examine the efficacy and acceptability of a smartphone application in eating disorder clinical treatment and if successful, should provide preliminary support for the use of smartphone applications over traditional paper food journals as a self-monitoring tool for augmenting specialty eating disorder clinical treatment.


Eligibility criteria:
inclusion criteria: * patients with an eating disorder (anorexia nervosa, bulimia nervosa, or eating disorder not otherwise specified) according to dsm-v criteria (american psychiatric association, 2013) as determined through a standard clinical interview by either a team psychiatrist or clinical psychologist, and validated with a self-report diagnostic measure. * patients with an apple or android smartphone (a mobile phone with access to third-party applications and advanced features) with an active data plan or frequent (e.g., daily) wi-fi access. * patients 17 years or older. * signed consent from patient. exclusion criteria: * patient has insufficient knowledge of english.

Keywords: eating disorders smartphone app mobile health recovery record cognitive behavioural therapy outpatient program self monitoring
a study to investigate the safety and efficacy of optivate® in children under 6 years of age with haemophilia a.

Conditions: Haemophilia A

Summary: the main objectives of this study are: * to assess optivate® consumption (iu/kg consumed per month for prophylactic and on-demand therapy and dose at each bleed). * to assess clinical outcome when treating a bleed with optivate®. * to evaluate optivate® in terms of clinical tolerance and safety in children under the age of 6 years. . * to assess fviii inhibitor development during the study.


Eligibility criteria:
inclusion criteria: * children under the age of 6 years with a diagnosis of severe haemophilia a. subjects who required fviii therapy and did not demonstrate inhibitors to fviii. children with history of inhibitors to fviii or clinically significant renal or liver disease were not eligible to participate in the study. exclusion criteria: -
treatment optimization and nephrolithiasis recurrence prevention with interdisciplinary care

Conditions: Kidney Stone

Summary: nearly 10% of the belgian population suffer from kidney stone disease. recent reviews reported that kidney stones represent an underestimated risk factor for further kidney function deterioration. preventive measures are recommended in lithiases patients to prevent the formation of new stones. the individual effects of different medicated prosthetic interventions have been documented in clinical trials. however, there is little data on the effectiveness of combining these different preventive measures in routine clinical practice (real-world context). patients with kidney stone disease require a complete metabolic assessment. the three main factors contributing to the stone's formation are the patient's metabolism, diet and lifestyle. metabolic work-up is recommended by the american urology association to identify and correct the factors responsible for urinary stone formation such as hypercalciuria, hyperoxaluria, hyperuricuria, hypocitraturia or abnormalities of urinary ph. the metabolic work-up includes at minimum the 24h urine test, a blood test and spot urine test. dietary habits and lifestyle are assessed by means of a questionnaire. the chu brugmann hospital has a specialized multidisciplinary clinic for renal lithiases and mineral metabolism. preventive personalized and interdisciplinary care in chu brugmann consists of a full metabolic work-up allowing the identification of lithogenic risk factors by nephrologists, dietary assessment by specialized dieticians and specific treatment protocol associated with regular follow-up. the aim of this study is to evaluate, in the context of a retrospective single-center cohort study, the effect of preventive personalized and interdisciplinary care on the evolution of all urinary lithogenic risk factors and the recurrence of kidney stones (rate of renal colics, emergency room admissions, and urological interventions).


Eligibility criteria:
inclusion criteria: * all patients of the chu brugmann hospital who fulfill the criteria of active or past history of kidney stone, from 01/01/2018 till 31/10/2023 * minimum follow-up time of 2 months with biochemical and clinical results available exclusion criteria: - none
dietary effects on weight loss and lipid profile in sedentary men

Conditions: Men; Life Style; Lipid Metabolism Disorders; Obesity; Overweight

Summary: negative-calorie diet is among the popular dieting guides for weight loss; however, there is still little knowledge about this method. the present study aimed to determine the effects of negative-calorie diet on weight loss and lipid profile, and to compare its efficiency with low-calorie diet in men.


Eligibility criteria:
inclusion criteria: * non-smokers * weight-stable (± 2 kg, for more than one year) * no history of regular exercise (in at least three months before the study). exclusion criteria: * history of medical disorders (cvd and other such as diabetes, depression, eating disorders, chronic medications, kidney disease, cancer, food allergies or intolerances to items used in meals, abnormality in thyroid or electrocardiograph * history of anti-obesity medication or weight loss drugs or dietary supplementations for weight control.

Keywords: dietary formulations lifestyle obesity overweight weight loss
the efficacy of neural stimulation in individuals with schizophrenia

Conditions: Schizophrenia; Schizo Affective Disorder

Summary: the purpose of this study is to understand the relationship between psychotic symptoms and social functioning in individuals with schizophrenia spectrum disorders. our goal is to determine whether stimulating the brain using transcranial direct current stimulation (tdcs) can improve symptoms and daily functioning.

paranoid ideation is a common delusion experienced by individuals with schizophrenia spectrum disorders (ssd) that negatively impacts social interactions and quality of life. therefore, efforts to reduce paranoid thinking via neuromodulation techniques \[e.g., transcranial direct current stimulation (tdcs)\] are in development, with amygdala-prefrontal cortex (pfc) circuits targeted as critical components of the neural mechanisms underlying paranoia. this project aims to alleviate paranoia and improve social functioning in individuals with ssd by implementing tdcs to ventrolateral pfc. a double-blind, within-subjects, crossover design will be used to compare the effects of active vs. sham tdcs. ecological momentary assessments (ema) will also be utilized to quantify any delayed stimulation effects in daily social interactions.

Eligibility criteria:
inclusion criteria: * age = 18-64 * diagnosed with schizophrenia or schizoaffective disorder * having current (in the past week) or recent (in the past month) paranoia exclusion criteria: * presence or history of a pervasive developmental disorder or mental retardation as defined by iq \< 70 * presence or history of neurological or medical disorders that contraindicate neural stimulation (e.g. presence or history of epilepsy, seizures, etc.) * demonstrating sensory limitations, including uncorrectable visual or hearing impairments that interfere with assessment * history of electroconvulsive therapy * lack of proficiency in english * substance use disorder not in remission in the past 6 months * any implanted devices such as pace maker, neurostimulator * pregnancy
a study for the collection of clinical data for stroke patients and healthy subjects

Conditions: Stroke; Health Behavior

Summary: this study aimes to medical data, musculoskeletal data and functional data over time of stroke patients and healthy subjects to compared the clinical differences between stroke and healthy subjects.


Eligibility criteria:
1. for stroke patients 1) inclusion criteria: * adults over 20 years of age * more than 1 month after onset of stroke * after hearing a detailed explanation of this study and fully understanding it, the subject or legal representative voluntarily decides to participate and agrees in writing to observe the precautions 2) exclusion criteria: * patients who correspond to one or more of the following cannot participate in the study. * patients with systemic infectious symptoms at the time of participation in the study * in the case of a person with impaired ability to consent (less than 10 points on the mmse), a person who is not accompanied by a guardian * those with severe medical conditions such as unstable conditions in the cardiovascular system, digestive system, respiratory system, endocrine system, etc., and those with poor general health * other cases where the researcher judges that participation in this study is not suitable(patients who are participating in other clinical trials or studies, or who have participated in other clinical trials or studies within the past 30 days can also participate in this study.) 2. for healthy voluteers 1) inclusion criteria: * over 20 years of age * a person who is performing an independent daily life * a person who voluntarily decides to participate and agrees in writing to abide by the precautions after hearing a detailed explanation of this study and fully understanding it 2) exclusion criteria: * patients who correspond to one or more of the following cannot participate in the study. * mmse score less than 20 points (from 19 points onwards excluded from study) * those who remain disabled due to brain disease (stroke, brain tumor, cerebral palsy, dementia, parkinson's disease, etc.) * those with severe medical conditions such as unstable conditions in the cardiovascular system, digestive system, respiratory system, endocrine system, etc., and those with poor general health * other cases where the researcher judges that participation in this study is not suitable (patients who are participating in other clinical trials or studies, or who have participated in other clinical trials or studies within the past 30 days can also participate in this study.)
the partner trial: placement of aortic transcatheter valve trial

Conditions: Critical Aortic Stenosis

Summary: the purpose of this study is to determine the safety and effectiveness of the device and delivery systems (transfemoral and transapical) in high risk, symptomatic patients with severe aortic stenosis.

subjects will undergo a physical exam and screening tests will be performed to determine if they are either a) a patient with a high surgical risk or b) not a candidate for surgery. they will then be randomized (like the flip of a coin) to have the investigational device implanted or to receive the current surgical or medical management available.

Eligibility criteria:
inclusion criteria cohort a 1. patients must have co-morbidities such that the surgeon and cardiologist co-pis concur that the predicted risk of operative mortality is ≥15% and/or a minimum sts score of 10 2. patient has senile degenerative aortic valve stenosis with echocardiographically derived criteria: mean gradient \>40 mmhg or jet velocity greater than 4.0 m/s or an initial aortic valve area of \< 0.8 cm2 3. patient is symptomatic from his/her aortic valve stenosis, as demonstrated by nyha functional class ii or greater 4. the subject or the subject's legal representative has been informed of the nature of the study, agrees to its provisions and has provided written informed consent as approved by the irb of the respective clinical site 5. the subject and the treating physician agree that the subject will return for all required post-procedure follow-up visits cohort b all candidates for cohort b of this study must meet #2, 3, 4, 5 of the above criteria and 6. the subject, after formal consults by a cardiologist and two cardiovascular surgeons agree that medical factors preclude operation, based on a conclusion that the probability of death or serious, irreversible morbidity exceeds the probability of meaningful improvement. specifically, the probability of death or serious, irreversible morbidity should exceed 50%. exclusion criteria 1. evidence of an acute myocardial infarction ≤ 1month before the intended treatment. 2. aortic valve is a congenital unicuspid or bicuspid valve; or is non-calcified 3. mixed aortic valve disease (aortic stenosis and aortic regurgitation with predominant aortic regurgitation \>3+). 4. any therapeutic invasive cardiac procedure performed within 30 days of the index procedure, (or 6 months if the procedure was a drug eluting coronary stent implantation). 5. pre-existing prosthetic heart valve in any position, prosthetic ring, or severe (greater than 3+) mitral insufficiency.

Keywords: valvular heart disease critical/severe aortic stenosis high risk symptomatic patients